Tango Therapeutics, Inc. 8-K

What Happened

• Tango Therapeutics, Inc. (TNGX) announced results of operations and financial condition for the quarter ended March 31, 2026 in a press release furnished as Exhibit 99.1 to an 8-K filed May 13, 2026.
• Separately, on May 13, 2026 the company reported board changes: Alexis Borisy resigned as a director, Lead Independent Director and Chair of the Compensation Committee, and Kanishka Pothula resigned as a director and member of the Nominating and Corporate Governance (NCG) Committee. The filing states neither resignation was due to any disagreement with the company.
• The Board appointed Sung Lee as Lead Independent Director, Chair of the Compensation Committee and as a member of the NCG Committee, effective May 13, 2026.

Key Details

• Press release relating to quarterly results for the period ended March 31, 2026 was furnished on May 13, 2026 (Exhibit 99.1).
• Alexis Borisy and Kanishka Pothula resigned effective May 13, 2026; resignations were not due to disagreements with the company.
• Sung Lee is now Lead Independent Director and Chair of the Compensation Committee; Compensation Committee members are Sung Lee, John Ketchum and Mace Rothenberg, M.D.
• NCG Committee members are now Mace Rothenberg, Sung Lee and Lesley Ann Calhoun.

Why It Matters

• The furnished press release means updated quarterly results and operational metrics are available for investors; review the release for revenue, earnings, cash runway, and other key financial details.
• Board leadership changes affect corporate governance and oversight—appointment of a new Lead Independent Director and Compensation Committee chair may influence executive compensation and board priorities.
• The filing’s note that resignations were not due to disagreements reduces immediate governance risk, but investors should monitor any further disclosures or proxy updates.